[关键词]
[摘要]
目的 探讨藤黄健骨胶囊联合唑来膦酸注射液治疗老年原发性骨质疏松的临床疗效。方法 选取2016年5月-2017年4月泸州市人民医院收治的老年原发性骨质疏松患者120例为研究对象,按照随机数字表法将所有患者分为对照组和治疗组,每组各60例。对照组静脉滴注唑来膦酸注射液,5 mg加入到生理盐水500 mL中,滴速30滴/min,静滴时间不低于30 min,1次/年。治疗组在对照组治疗基础上口服藤黄健骨胶囊,1 g/次,2次/d。两组患者连续治疗12个月。观察两组的临床疗效,比较两组的血清因子水平、骨密度(BMD)、视觉模拟评分法(VAS)评分。结果 治疗后,对照组和治疗组的总有效率分别为78.33%、91.67%,两组比较差异有统计学意义(P<0.05)。治疗后,两组基质金属蛋白酶13(MMP-13)、MMP-13/TIMP-1显著降低,金属蛋白酶抑制因子(TIMP-1)明显升高,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组血清因子水平明显优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组腰椎、股骨颈、Wards三角区的BMD明显升高,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组BMD明显高于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组VAS评分明显降低,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组VAS评分明显低于对照组,两组比较差异具有统计学意义(P<0.05)。结论 藤黄健骨胶囊联合唑来膦酸注射液治疗老年原发性骨质疏松具有较好的临床疗效,可调节骨代谢指标,提高骨密度,减少疼痛,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To investigate the clinical effect of Tenghuang Jiangu Capsules combined with Zoledronic Acid Injection in treatment of senile primary osteoporosis. Methods Patients (120 cases) with senile primary osteoporosis in Luzhou People's Hospital from May 2016 to April 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were iv administered with Zoledronic Acid Injection, 5 mg added into normal saline 500 mL, the drop speed was 30 drops/min, and the drop time was not less than 30 min, once yearly. Patients in the treatment group were po administered with Tenghuang Jiangu Capsules on the basis of the control group, 1 g/time, twice daily. Patients in two groups were treated for 12 months. After treatment, the clinical efficacies were evaluated, and serum levels of factors, BMD, and VAS scores in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 78.33% and 91.67%, respectively, and there was difference between two groups (P<0.05). After treatment, MMP-13 and MMP-13/TIMP-1 levels in two groups were significantly decreased, but the TIMP-1 levels in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the serum levels of factors in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the BMD of lumbar vertebrae, femoral neck and Wards triangle in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the BMD in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, VAS scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the VAS scores in the treatment group were significantly lower than that in the control group, with significant difference between two groups (P<0.05). Conclusion Tenghuang Jiangu Capsules combined with Zoledronic Acid Injection has clinical curative effect in treatment of senile primary osteoporosis, can regulate bone metabolism index, increase BMD, and reduce patient's pain, which has a certain clinical application value.
[中图分类号]
[基金项目]